Antibotulinum neurotoxin Mabs production processes defined.

Xoma received final acceptance from the NIAID of all deliverables under its contract. This $15-million contract with NIAID was awarded to Xoma in March, 2005, to develop manufacturing processes for three antibotulinum neurotoxin Mabs.

With the completion of this first contract, Xoma has created production cell lines using its antibody expression systems, built and qualified master and manufacturer’s working cell banks, and developed production processes for and produced initial cGMP quantities of the three antibodies.

Previous articleES Cell-Qualified Growth Media and Supplements Alliance Inked
Next articleSRI International Recipient of $56.9M from the NIAID